Recent studies suggest that anti-inflammatory medication may play a role in the treatment of mood disorders.
Aims:
The purpose of this study was to determine the efficacy of anti-inflammatory drugs in patients with major depressive disorder and bipolar disorder.
Method:
The Cochrane Central Register of Controlled Trials, PubMed, EMBASE, PsychINFO and Clinicaltrials.gov were searched from inception until 15 April 2017 for completed and on-going randomized controlled trials of anti-inflammatory agents for major depressive disorder and bipolar disorder. Data from randomized controlled trials assessing the antidepressant and anti-manic effect of adjunctive mechanistically diverse anti-inflammatory agents were pooled to determine standard mean differences (SMDs) compared with placebo and/or treatment as usual.
Results:
Patients receiving anti-inflammatory agents showed lower post-treatment depressive symptom scores compared with those receiving placebo with a standard mean difference of −0.71 (six randomized controlled trials, n=214, 95% CI −1.24 to −0.17, p=0.009). Anti-inflammatory treatment was found to reduce post-treatment manic symptom scores with a standard mean difference of −0.72 (three randomized controlled trials, n=96, 95% CI −1.31 to −0.13, p=0.02). Anti-inflammatories did not show a statistically significant improvement in the secondary outcome measure (change in symptom scores from baseline to outcome).
Conclusions:
Further high quality trials are needed before making recommendations for the routine clinical use of anti-inflammatories in the treatment of mood disorders.
AbbasiSHHosseiniFModabberniaAet al. (2012) Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study. J Affect Disord141: 308–314.
2.
AkhondzadehSJafariSRaisiFet al. (2009) Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial. Depress Anxiety26: 607–611.
3.
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders (5th ed). Washington, DC: American Psychiatric Association.
4.
AppletonKMRogersPJNessAR (2010) Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr91: 757–770.
5.
ArabzadehSAmeliNZeinoddiniAet al. (2015) Celecoxib adjunctive therapy for acute bipolar mania: A randomized, double-blind, placebo-controlled trial. Bipolar Disord17: 606–614.
6.
AyorechZTracyDKBaumeisterDet al. (2015) Taking the fuel out of the fire: Evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders. J Affect Disord174: 467–478.
7.
BaumeisterDRussellAParianteCMet al. (2014) Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors. Soc Psychiatry Psychiatr Epidemiol49: 841–849.
8.
BerkMCopolovDLDeanOet al. (2008) N-acetyl cysteine for depressive symptoms in bipolar disorder: A double-blind randomized placebo-controlled trial. Biol Psychiatry64: 468–475.
BerkMDeanOMCottonSMet al. (2014) The efficacy of adjunctive N-acetylcysteine in major depressive disorder: A double-blind, randomized, placebo-controlled trial. J Clin Psychiatry75: 628–636.
11.
CarvalhoLABerginkVSumaskiLet al. (2014) Inflammatory activation is associated with a reduced glucocorticoid receptor alpha/beta expression ratio in monocytes of inpatients with melancholic major depressive disorder. Transl Psychiatry4: e344. doi: 10.1038/tp.2013.118.
12.
Cochrane Collaboration (2011) Review manager (RevMan) [Computer program]. Version [5.1]Copenhagen: The Nordic Cochrane Centre. Available at: http://ims.cochrane.org.
13.
DantzerRO’ConnorJCFreundGGet al. (2008) From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci9: 46–56.
14.
DeanOGiorlandoFBerkM (2011) N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci36: 78–86.
15.
DeanOMBushAICopolovDLet al. (2012) Effects of N-acetyl cysteine on cognitive function in bipolar disorder. Psychiatry Clin Neurosci66: 514–517.
16.
DeanOMMaesMAshtonMet al. (2014) Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: A double blind, randomised, placebo controlled trial. Clin Psychopharmacol Neurosci12: 180–188.
17.
DerSimonianRLairdN (1986) Meta-analysis in clinical trials. Control Clin Trials7: 177–188.
18.
DowlatiYHerrmannNSwardfagerWet al. (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry67: 446–457.
19.
Effective Public Health Practice Project (1998) Quality Assessment Tool For Quantitative Studies. Hamilton, ON: Effective Public Health Practice Project. Available at: http://www.ephpp.ca/index.html
20.
EggerMDavey SmithGSchneiderMet al. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ315: 629–634.
21.
Emadi-KouchakHMohammadinejadPAsadollahi-AminAet al. (2016) Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: A double-blind, placebo-controlled, randomized trial. Int Clin Psychopharmacol31: 20–26.
22.
FaridhosseiniFSadeghiRFaridLet al. (2014) Celecoxib: A new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol29: 216–223.
23.
FariesDHerreraJRayamajhiJet al. (2000) The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res34: 3–10.
24.
FondGHamdaniNKapczinskiFet al. (2014) Effectiveness and tolerance of anti-inflammatory drugs’ add-on therapy in major mental disorders: A systematic qualitative review. Acta Psychiatrica Scandinavica129: 163–179.
25.
GarnerSEEadyABennettCet al. (2012) Minocycline for acne vulgaris: Efficacy and safety. Cochrane Database Syst RevCD002086. doi: 10.1002/14651858.CD002086.pub2.
26.
GeddesJRMiklowitzDJ (2013) Treatment of bipolar disorder. Lancet381: 1672–1682.
27.
GoldsmithDRRapaportMHMillerBJ (2016) A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry21: 1696–1709.
28.
GoldsteinBIKempDESoczynskaJKet al. (2009) Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: A systematic review of the literature. J Clin Psychiatry70: 1078–1090.
29.
GrosseLCarvalhoLAWijkhuijsAJet al. (2015) Clinical characteristics of inflammation-associated depression: Monocyte gene expression is age-related in major depressive disorder. Brain Behav Immun44: 48–56.
30.
GrosseLCarvalhoLABirkenhagerTKet al. (2016) Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy. Psychopharmacology233: 1679–1688.
31.
HalarisAAlviNMereshEet al. (2014) Inflammation control reverses treatment-resistance in bipolar depression. Neurol Psychiatry Brain Res20: 12–13.
32.
HigginsJPThompsonSGDeeksJJet al. (2003) Measuring inconsistency in meta-analyses. BMJ327: 557–560.
33.
HigginsJPTGreenS (eds) (2011, March) Cochrane Handbook for Systematic Reviews of Interventions Version [5.1.0]. The Cochrane Collaboration. Available at: www.cochrane-handbook.org
34.
HowrenMBLamkinDMSulsJ (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom Med71: 171–186.
35.
HusainMIChaudhryIBHamiraniMMet al. (2016) Minocycline and celecoxib as adjunctive treatments for bipolar depression: A study protocol for a multicenter factorial design randomized controlled trial. Neuropsychiatr Dis Treat13: 1–8.
36.
HusainMIChaudhryIBRahmanRRet al. (2015) Minocycline as an adjunct for treatment-resistant depressive symptoms: Study protocol for a pilot randomised controlled trial. Trials16: 410.
37.
JafariSAshrafizadehSGZeinoddiniAet al. (2015) Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: A double-blind, placebo-controlled, randomized trial. J Clin Pharm Ther40: 441–446.
38.
KargarMYoosefiAAkhondzadehSet al. (2015) Effect of adjunctive celecoxib on BDNF in manic patients undergoing electroconvulsive therapy: A randomized double blind controlled trial. Pharmacopsychiatry48: 268–273.
39.
KashaniLOmidvarTFarazmandBet al. (2013) Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology38: 767–776.
40.
KohlerOBenrosMENordentoftMet al. (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry71: 1381–1391.
41.
LindeKKristonLRuckerGet al. (2015) Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: Systematic review and network meta-analysis. Ann Fam Med13:69–79.
42.
MagalhãesPVDeanOMBushAIet al. (2011a) N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr33: 374–378.
43.
MagalhãesPVDeanOMBushAIet al. (2011b) N-acetyl cysteine add-on treatment for bipolar II disorder: A subgroup analysis of a randomized placebo-controlled trial. J Affect Disord129: 317–320.
44.
MagalhãesPVDeanOMBushAIet al. (2013) A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania. Aust N Z J Psychiatry47: 564–568.
45.
MajidMHashemianFHosseiniSMet al. (2015) A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in treatment of drug-naive depressed women: A pilot study. Iran J Pharm Res14: 891–899.
46.
MalhiGSIvanovskiBHadzi-PavlovicDet al. (2007) Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disorders9: 114–125.
47.
MarottaAChiaieRDSpagnaAet al. (2015) Impaired conflict resolution and vigilance in euthymic bipolar disorder. Psychiatry Res229: 490–496.
48.
MillerAHRaisonCL (2016) The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nat Rev Immunol16: 22–34.
49.
MiyaokaTWakeRFuruyaMet al. (2012) Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study. Prog Neuropsychopharmacol Biol Psychiatry37: 222–226.
50.
MohammadinejadPAryaPEsfandbodMet al. (2015) Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients: A double-blind, placebo-controlled, randomized trial. Ann Pharmacother49: 953–961.
51.
MoherDShamseerLClarkeMet al; PRISMA-P Group (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev4: 1. doi: 10.1186/2046-4053-4-1.
52.
MousaviSYKhezriRKarkhaneh-YousefiMAet al. (2017) A randomized, double-blind placebo-controlled trial on effectiveness and safety of celecoxib adjunctive therapy in adolescents with acute bipolar mania. J Child Adolesc Psychopharmacol. Epub ahead of print 14April2017. doi: 10.1089/cap.2016.0207.
53.
MukherjeeDNissenSETopolEJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA286: 954–959.
54.
MüllerNSchwarzMJDehningSet al. (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry11: 680–684.
55.
MunkholmKBraunerJVKessingLVet al. (2013) Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis. J Psychiatr Res47: 1119–1133.
56.
NeryFGMonkulESHatchJPet al. (2008) Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study. Hum Psychopharmacol23: 87–94.
57.
NgQXKohSSChanHWet al. (2017) Clinical use of curcumin in depression: A meta-analysis. J Am Med Dir Assoc18: 503–508.
58.
O’NeilASannaLRedlichCet al. (2012) The impact of statins on psychological wellbeing: A systematic review and meta-analysis. BMC Med10: 154.
59.
O’DonovanARushGHoatamGet al. (2013) Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety30: 307–314.
60.
RaghuvanshiVSNischalAPantKKet al. (2013) A randomized controlled study to evaluate the efficacy of celecoxib add-on in patients of depression partially responding to escitalopram. Indian J Pharmacol45: S243pp.
61.
RaisonCLRutherfordREWoolwineBJet al. (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry70: 31–41.
62.
RosenblatJDKakarR1BerkMet al. (2016) Anti-inflammatory agents in the treatment of bipolar depression: A systematic review and meta-analysis. Bipolar Disord18: 89–101.
63.
RushAJTrivediMHWisniewskiSRet al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry163: 1905–1917.
64.
SaroukhaniSEmami-ParsaMModabberniaAet al. (2013) Aspirin for treatment of lithium-associated sexual dysfunction in men: Randomized double-blind placebo-controlled study. Bipolar Disord15: 650–656.
65.
SavitzJPreskornSTeagueTKet al. (2012) Minocycline and aspirin in the treatment of bipolar depression: A protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial. BMJ Open2: e000643.
66.
SepanjniaKModabberniaAAshrafiMet al. (2012) Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: Randomized double-blind placebo-controlled trial. Neuropsychopharmacology37: 2093–2100.
67.
SoczynskaJKMansurRBBrietzkeEet al. (2012) Novel therapeutic targets in depression: Minocycline as a candidate treatment. Behav Brain Res235: 302–317.
68.
SongCDinanTLeonardBE. (1994) Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J Affect Disord30: 283–288.
69.
StrawbridgeRArnoneDDaneseAet al. (2015) Inflammation and clinical response to treatment in depression: A meta-analysis. Eur Neuropsychopharmacol25: 1532–1543.
70.
SuSCSunMTWenMJet al. (2011) Brain-derived neurotrophic factor, adiponectin, and proinflammatory markers in various subtypes of depression in young men. Int J Psychiatry Med42: 211–226.
71.
VergunstFKFekaduAWoodersonSCet al. (2013) Longitudinal course of symptom severity and fluctuation in patients with treatment-resistant unipolar and bipolar depression. Psychiatry Res207: 143–149.
72.
WaterdrinkerABerkMVenugopalKet al. (2015) Effects of N-Acetyl cysteine on suicidal ideation in bipolar depression. J Clin Psychiatry76: 665
73.
WhitefordHADegenhardtLRehmJet al. (2013) Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010. Lancet382: 1575–1586.
74.
WolfeMMLichtensteinDRSinghG (1999) Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med340: 1888–1899.
75.
World Health Organization (1992) The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization.
76.
ZeinoddiniASorayaniMHassanzadehEet al. (2015) Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: A randomized, double-blind, placebo-controlled trial. Depress Anxiety32: 167–173.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
